General Information
When is the submission deadline?
The submission deadline is Thursday, May 7 at 5 p.m. EDT. The late breaker submission deadline is Thursday, August 13, 5 p.m. EDT.
Who can I contact for technical support with the submission site?
For technical support with the submission site, please call (Direct) (410) 638-9239 or (Toll Free) (877) 426-6323 between the hour of 9 a.m. – 9 p.m. ET, Mon – Fri, or email Help@ConferenceAbstracts.com.
What is the abstract submission fee?
There is no fee to submit an abstract.
Should I register for IDWeek to present my abstract?
All abstract presenters must register to attend IDWeek. Every accepted abstract must be presented by a registered attendee at IDWeek.
What is a late breaker abstract?
Late breaker abstracts are highly competitive; only abstracts containing new, novel, cutting-edge information will be considered. Retrospective studies will not be considered. Because of the nature of late breakers, IDWeek will accept very few submissions for presentation, less than 10 percent. All late breaker abstracts must be submitted online. Authors of late breaker abstracts are not eligible to apply for IDWeek travel grants or awards. Late breaker submission will begin by June 1.
Can I add a QR code to my poster?
Yes, you may add a QR code to your poster.
How long can my abstract be? Can I include images?
The abstract character limit is 1950 (spaces are not counted). Title and authors do not count against the 1950 character limit. Figures are accepted and they do not count towards character limit. You are limited to three images in one abstract. There isn’t a maximum allowed resolution for figures. Acceptable file types for images are .gif, .jpg, and .png. Color images are allowed. Please provide high resolution images.
How many abstracts can I submit?
There is no limit to the number of abstracts an author can submit.
Can I revise my abstract?
Revisions to your submission can be made before the submission deadline, Thursday, May 7, at 5 p.m. EDT (Thursday, August 13, at 5 p.m. for late breaker abstracts). No changes will be accepted after this deadline. In order to make changes to your abstract prior to the deadline, you must follow the link to your submission found in your submission confirmation email. To make a change select one of the eight steps to submit an abstract and save your changes. You will not receive a new confirmation email.
Can I add an author or remove an author from my abstract?
Authors can be changed before the submission deadline, Thursday, May 7, at 5 p.m. EDT (Thursday, August 13, at 5 p.m. for late breaker abstracts). Requests after this date will not be accommodated.
Is my submission complete?
Your submission is complete and when you select “Conclude Submission” at the end of the abstract submission process. On the screen you will see the message, “Your abstract submission has been received.” You will also receive an email with your abstract number and the link to go back and review your submission. You may update or make changes to your abstract up until the submission deadline, Thursday, May 7, at 5 p.m. EDT (Thursday, August 13, at 5 pm. for late breaker abstracts).
Can I request my abstract be presented on a certain day or time?
Unfortunately, we are unable to accommodate date/time presentation requests. You may have a co-author or colleague present your abstract if you are unable to attend and do not wish to withdraw.
How do I cite an IDWeek abstract?
The following is a suggested style for citing IDWeek abstracts:
Example Only
Presenter(s). Title. [Paper/Poster/Talk] presented at IDWeek; October 3-7, 2018; San Francisco, CA. http://www.idweek.org
Abstracts from previous IDWeek Meetings are available through the Interactive Program for that year (Visit the Past and Future Events page for the link). In your abstract citation, use the appropriate URL for the meeting in which the abstract was presented.
When can I get into the Poster Hall to set up my poster? When must I remove my poster?
This information will be provided closer to the date of the conference.
Poster Presentations
Poster sessions are abstracts that have been selected and grouped together by category/topics. Poster presentations give authors an opportunity to acquaint attendees and experts in the field with the fundamentals of their abstracts and research. Presenting authors are required to be present at their poster boards for one and a half hours on assigned dates.
Oral Presentations
The presenting author is expected to discuss his or her scientific research and summarize the data into a comprehensive 10-minute presentation, with five minutes designated for questions and answers. Presenting authors are required to use PowerPoint slides to accompany their oral presentations.
Late Breaker Abstract
Late breaker abstracts are intended for new, cutting-edge science that was not ready to submit at the regular abstract deadline. Because of the nature of late breakers, IDWeek will accept very few submissions for presentation, less than 10 percent. Retrospective studies will not be considered. Late breaker abstracts are always oral presentations and authors of late breaker abstracts are not eligible to apply for IDWeek travel grants or awards. Late breaker submission will begin on June 1.
IDWeek Hot Zone
The IDWeek Hot Zone will feature 30 minute poster sessions, featuring 6 rapid fire poster presentations each, in one of two Hot Zone Arenas in the Poster Hall. More information will be available in Spring 2020.
A: Antimicrobial Agents Including Antibacterial, Antiviral and Antifungal Drugs
A1. Novel agents
A2. PK/PD studies
A3. Resistance mechanisms
A4. Treatment antimicrobial resistant infections
A5. Pharmacogenetics
B: Basic Science and Translational Studies of Microbial Pathogenesis and Infectious Diseases
B1. Studies of correlates of protection (or biomarkers) against microbial infection and disease in patients or experimental models
B2. Studies of the immune response to microbial infection and disease in patients or experimental models
B3. Studies of genetic factors that govern susceptibility to microbial infection and disease
B4. Studies of microbial factors that govern susceptibility to microbial infection and disease
B5. Studies at the interface of host-microbe interaction
B6. Microbiome science
C: Clinical Infectious Diseases
C1. Clinical trials
C2. Bone and joint
C3. Skin and soft tissue
C4. Respiratory infections – viral
C5. Respiratory infections – bacterial
C6. Enteric infection
C7. Bacteremia
C8. Endocarditis
C9. CNS infection
C10. Sexually transmitted infections
C11. UTIs
D: Infectious Disease Diagnostics
E.g., all aspects of adult and pediatric diagnostic microbiology, rapid diagnostics, molecular diagnostics, host response signatures as diagnostics, molecular imaging, nanotechnology, next generation sequencing, genomics/proteomics, and other advanced technologies for detection of infectious diseases
D1. Bacteriology/mycobacteriology
D2. Virology
D3. Parasitology
D4. Mycology
D5. Typing/sequencing
D6. Other (e.g., host response biomarkers, molecular imaging, metabolomics/proteomics, etc.)
E: Infectious Diseases Medical Education
(scholarly work directed at enhancing infectious diseases education of trainees and/or health professionals)
F: Hepatitis
(all HIV co-infection abstracts should be submitted to Category H)
F1. Hepatitis A
F2. Hepatitis B
F3. Hepatitis C
G: Global Health
(e.g., travel medicine, tropical medicine and parasitology, endemic/epidemic diseases of resource-challenged areas)
H: HIV/AIDS, other retroviruses, and co-infections
H1. Epidemiology and screening
H2. Prevention
H3. Pathogenesis
H4. Treatment
H5. Complications and co-infections
I: Adult and Pediatric Vaccines
I1. Adult Vaccines
I2. Pediatric Vaccines
I3. Adolescent Vaccines
J: Clinical Practice Issues
(e.g., billing, medical records & informatics, healthcare reform, home health/OPAT)
K: Tuberculosis and other Mycobacterial Infections
There are no subcategories for category K
L: New Agents/Trials
L1. New drug development
L2. New diagnostics
L3. New vaccines
M: Medical Mycology
M1. Clinical studies of fungal infections
M2. Studies of fungal pathogenesis in patients with immune impairment
M3. Studies of the pathogenesis of fungal infections
N: Healthcare Epidemiology and Prevention
N1. HAI: Occupational Infection Prevention
N2. HAI: Surveillance
N3. HAI: Epidemiologic Methods
N4. HAI: Device-Associated (CLABSI, CAUTI, VAP)
N5. HAI: Disinfection/Sterilization & Environmental Infection Prevention
N6. HAI: Hand Hygiene/Transmission-Based Precautions
N7. HAI: Surgical Site Infections
N8. HAI: C. difficile
N9. HAI: Gram-positives (MRSA, MSSA, VRE)
N10. HAI: Gram-negatives (MDR-GNR)
N11. HAI outbreaks
N12. HAI: Non-Acute Care
N13. HAI: Non-Bacterial (Fungal, Viral)
O: Public Health
(Studies on issues pertaining to preparedness for and response to outbreaks of infectious diseases including those linked to agents of bioterror, foodborne, waterborne, vectorborne, and zoonotic diseases, and vaccine-preventable diseases.)
P: Pediatric and Perinatal Infections
P1. Bacterial studies (natural history and therapeutic)
P2. Fungal studies (natural history and therapeutic)
P3. Viral studies (natural history and therapeutic)
P4. Antimicrobial stewardship (inpatient/outpatient pediatric focused)
P5. Healthcare-associated infection epidemiology and prevention
P6. HIV
P7. Maternal-child infections
S: Antimicrobial Stewardship, including quality of care
S1. Antibiotic Stewardship: Program Development & Evaluation
S2. Antibiotic Stewardship: Interventions
S3. Antibiotic Stewardship: Diagnostics/Diagnostic Stewardship
S4. Antibiotic Stewardship: Special Populations
S5. Antibiotic Stewardship: Non-Inpatient Settings
S6. Antibiotic Stewardship: Trends in Antimicrobial Prescribing
T: Transplant and Immunocompromised Host Infections
T1. Studies of pre-transplant screening and evaluation
T2. Studies of empiric and pre-emptive therapy
T3. Studies of the epidemiology of infections in transplant patients and patients with impaired immunity due to underlying disease or immunosuppressive drugs
V: Virology (all viruses other than HIV, HIV co-infections, and hepatitis)
V1. Studies of the epidemiology of viral infections
V2. Studies of viral pathogenesis
V3. Studies of treatment and prevention of viral infections
- Administration
- Biology or Biological
- Center
- Centers for Disease Control and Prevention
- Clinic or Clinical
- College
- Corporation
- Development
- Education
- U.S. Food and Drug Administration
- Foundation
- General
- Hospital(s)
- Incorporated
- Institute(s) or Institution
- International
- Medical or Medicine
- Memorial
- Microbiology or Microbiological
- National
- National Cancer Institute
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- Public
- Research
- School
- Science(s)
- University
- U.S. Department of Agriculture
- Veterans Administration
- Admin.
- Biol.
- Ctr.
- CDC
- Clin.
- Coll.
- Corp.
- Dev.
- Ed.
- U.S. FDA
- Fndn.
- Gen.
- Hosp.
- Inc.
- Inst.
- Intl.
- Med.
- Mem.
- Microbiol.
- Natl.
- NCI
- NIH
- NIAID
- Publ.
- Res.
- Sch.
- Sci.
- Univ.
- U.D. DA
- VA
Previous IDWeek Abstracts
IDWeek 2019 Abstracts in Open Forum Infectious Diseases, OFID
IDWeek 2018 Abstracts in Open Forum Infectious Diseases, OFID
IDWeek 2017 Abstracts in Open Forum Infectious Diseases, OFID
IDWeek 2016 Abstracts in Open Forum Infectious Diseases, OFID
IDWeek 2015 Abstracts in Open Forum Infectious Diseases, OFID
IDWeek 2014 Abstracts in Open Forum Infectious Diseases, OFID
